First-round funding for eye technology firm HyperBranch
This article was originally published in Clinica
Executive Summary
HyperBranch Medical Technology, a Raleigh, North Carolina-based developer of eye surgery products, has raised $6m in a first round of venture capital financing. The funds, contributed by The Aurora Funds (Durham, North Carolina) and HIG Ventures (Miami, Florida), will help the company carry out preclinical and clinical development of its two lead products, a synthetic lens for use in cataract surgery and wound-sealing glue for use in ophthalmics.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.